SynthesisFrontiers in public health2025
Meditation for subjective cognitive decline, mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Redirecting Alzheimer's disease therapeutics: Multitarget drugs and complementary non-pharmacological strategies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Meditation has gained increasing recognition as a simple, cost-effective, and non-invasive therapeutic approach for older adults with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and Alzheimer's disease (AD). This meta-analysis aimed to systematically evaluate its effectiveness on this population. Methods: A comprehensive search across nine databases was performed from inception to April 1, 2024, to identify eligible randomized controlled trials (RCTs). The primary outcome was global cognitive performance measured by the Mini-Mental State Examination (MMSE), while the secondary outcomes included sleep quality estimated through the Pittsburgh Sleep Quality Index (PSQI), health status assessed using the 36-Item Short Form Health Survey (SF-36), and depression evaluated with the Geriatric Depression Scale (GDS). This meta-analysis utilized R 4.3.1 software and adhered to the Cochrane Handbook and PRISMA reporting guidelines. Results: A total of 25 RCTs published between 2013 and 2024 involving 2,095 participants were included in this study. The pooled findings demonstrated that meditation significantly improved global cognitive performance (MD 2.22, 95% CI: 0.83-3.62, Conclusion: This meta-analysis suggests that meditation is an effective adjunct therapy for improving global cognitive performance, sleep quality, and health status in older adults with SCD, MCI, and AD. However, given the heterogeneity and limited sample sizes, these findings should be interpreted with caution. More large-scale and high-quality RCTs are needed to further substantiate these effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.